{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-022227","form_type":"8-K","ticker":"CELC","cik":"0001603454","company_name":"Celcuity Inc.","filed_at":"2024-05-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.177435+00:00","generated_at":"2026-06-01T07:10:30.475867+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Celcuity prices $60M common stock offering of 3.871M shares at $15.50","bullets":["3,871,000 shares priced at $15.50 per share; gross proceeds $60.0M, net ~$56.2M.","Proceeds to fund working capital, R&D, and Phase 3 trial of gedatolisib for HR+/HER2- advanced breast cancer.","Investors include BVF Partners, Vivo Capital, Eventide Asset Management, Samlyn Capital, Driehaus Capital, Blue Owl Healthcare.","Offering closed May 31, 2024; existing cash plus proceeds expected to fund operations through at least H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-022227","json":"https://secwatch.observer/filing/0001493152-24-022227.json","markdown":"https://secwatch.observer/filing/0001493152-24-022227.md","text":"https://secwatch.observer/filing/0001493152-24-022227.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1603454/000149315224022227/0001493152-24-022227-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1603454/000149315224022227/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:10:30.475867+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}